King of Prussia’s iCeutica Inc. is licensing its SoluMatrix Fine Patricle Technology to a nearby pharmaceutical company that produces low-dose nonsteroidal anti-inflammatory drugs for pain relief, writes John Luciew of the Harrisburg Patriot-News.
Iroko Pharmaceuticals, a global pharmaceutical company based in the Philadelphia Naval Shipyard, uses iCeutica’s technology to develop a suite of drugs as a non-opioid alternative to pain management.
According to Luciew, treating pain is a constant in medicine, and a part of the human condition, known as the “fifth vital sign” among physicians. Effectively treating pain amidst the nation’s rapid rise in opioid addiction has been a challenge.
Iroko might just have the solution, a viable alternative to opioids, thanks to iCeutica.
By harnessing nanotechnology and small-particles physics, Iroko is developing a new class of low-dose prescription painkillers. These painkillers are predicated upon a highly patented process of pulverizing drug molecules so they are up to 100 times smaller, which markedly increases their pain-killing effectiveness at dramatically lower doses.
iCeutica owns the patented SoluMatrix fine particle process that pulverizes drug molecules into nano-sized particles, enabling low doses of a drug to be better absorbed by the body, thus providing faster and far more effective pain relief.
“The practice of crushing and grinding drug powders is as old as the pharmacist’s mortar and pestle,” writes Luciew. “But there’s never been a way of pulverizing a drug molecule into nano particles that was scalable for industrial production – not until iCeutica created its SoluMatrix process, that is.”
Click here to read more about the iCeutica’s role in helping our nation curb its opioid addiction in the Harrisburg Patriot-News.